Sansregret Laurent, Patterson James O, Dewhurst Sally, López-García Carlos, Koch André, McGranahan Nicholas, Chao William Chong Hang, Barry David J, Rowan Andrew, Instrell Rachael, Horswell Stuart, Way Michael, Howell Michael, Singleton Martin R, Medema René H, Nurse Paul, Petronczki Mark, Swanton Charles
The Francis Crick Institute, London, United Kingdom.
The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Cancer Discov. 2017 Feb;7(2):218-233. doi: 10.1158/2159-8290.CD-16-0645. Epub 2017 Jan 9.
Intercellular heterogeneity, exacerbated by chromosomal instability (CIN), fosters tumor heterogeneity and drug resistance. However, extreme CIN correlates with improved cancer outcome, suggesting that karyotypic diversity required to adapt to selection pressures might be balanced in tumors against the risk of excessive instability. Here, we used a functional genomics screen, genome editing, and pharmacologic approaches to identify CIN-survival factors in diploid cells. We find partial anaphase-promoting complex/cyclosome (APC/C) dysfunction lengthens mitosis, suppresses pharmacologically induced chromosome segregation errors, and reduces naturally occurring lagging chromosomes in cancer cell lines or following tetraploidization. APC/C impairment caused adaptation to MPS1 inhibitors, revealing a likely resistance mechanism to therapies targeting the spindle assembly checkpoint. Finally, CRISPR-mediated introduction of cancer somatic mutations in the APC/C subunit cancer driver gene CDC27 reduces chromosome segregation errors, whereas reversal of an APC/C subunit nonsense mutation increases CIN. Subtle variations in mitotic duration, determined by APC/C activity, influence the extent of CIN, allowing cancer cells to dynamically optimize fitness during tumor evolution.
We report a mechanism whereby cancers balance the evolutionary advantages associated with CIN against the fitness costs caused by excessive genome instability, providing insight into the consequence of CDC27 APC/C subunit driver mutations in cancer. Lengthening of mitosis through APC/C modulation may be a common mechanism of resistance to cancer therapeutics that increase chromosome segregation errors. Cancer Discov; 7(2); 218-33. ©2017 AACR.See related commentary by Burkard and Weaver, p. 134This article is highlighted in the In This Issue feature, p. 115.
细胞间异质性因染色体不稳定性(CIN)而加剧,促进了肿瘤异质性和耐药性。然而,极端的CIN与癌症预后改善相关,这表明肿瘤中适应选择压力所需的核型多样性可能与过度不稳定的风险相平衡。在这里,我们使用功能基因组学筛选、基因组编辑和药理学方法来鉴定二倍体细胞中的CIN存活因子。我们发现部分后期促进复合物/细胞周期体(APC/C)功能障碍会延长有丝分裂,抑制药理学诱导的染色体分离错误,并减少癌细胞系中或四倍体化后自然出现的滞后染色体。APC/C损伤导致对MPS1抑制剂的适应性,揭示了针对纺锤体组装检查点的治疗可能的耐药机制。最后,CRISPR介导的在APC/C亚基癌症驱动基因CDC27中引入癌症体细胞突变可减少染色体分离错误,而APC/C亚基无义突变的逆转会增加CIN。由APC/C活性决定的有丝分裂持续时间的细微变化会影响CIN的程度,使癌细胞在肿瘤进化过程中动态优化适应性。
我们报告了一种机制,通过该机制癌症平衡了与CIN相关的进化优势与过度基因组不稳定导致的适应性成本,为癌症中CDC27 APC/C亚基驱动突变的后果提供了见解。通过APC/C调节延长有丝分裂可能是对增加染色体分离错误的癌症治疗产生耐药性的常见机制。癌症发现;7(2);218 - 33。©2017 AACR。见Burkard和Weaver的相关评论,第134页。本文在本期特刊第115页重点介绍。